Efficacy & Safety of Albumin Paclitaxel Combined With Cisplatin

Status Active, not recruiting

Clinical Trial Summary

Non-resectable stage III non-small cell lung cancer is recommended for concurrent chemoradiotherapy. Paclitaxel and platinum are commonly used in chemotherapy regimens. The aim of this study was to investigate whether paclitaxel albumin combined with cisplatin combined with three-dimensional primary radiotherapy could improve short-term efficacy, local progression-free survival, and reduce treatment-related toxicity. To determine whether paclitaxel albumin combined with cisplatin regimen can be used as a first-line treatment for stage III non-small cell lung cancer with concurrent primary thoracic radiotherapy

Clinical Trial Description

Control group: Paclitaxel 175 mg/m2 was injected into saline solution on the first day. Cisplatin 75 mg/m2 was given intravenously for 2-3 days (2-4 days), carboplatin 300 mg/m2 and 2 days. (Because toxicity and heart problems can replace DDP)]Repeated every 3-4 weeks for 4 consecutive cycles (21-28 days/cycle, minimum 2 cycles). In the experimental group, albumin paclitaxel 40 mg/m2/week was injected into saline at the same time as radiotherapy, once a week. Cisplatin 75 mg/m2 was given intravenously for 2-3 days (2-4 days), carboplatin 300 mg/m2 and 2 days. (Because toxicity and heart problems can replace DDP)] Repeat every 3-4 weeks for 4 consecutive cycles (21-28 days/cycle, minimum 2 cycles). Three-dimensional radiotherapy: intensity-modulated radiotherapy (IMRT) or rotational intensity-modulated radiation therapy (VMAT) segmented dose: primary focus and mediastinal metastatic lymph nodes; segmented mode: continuous accelerated hypersegmentation Dose: DTGTV: > 60Gy treatment sequence: Chemotherapy started within one week after completion of pre-treatment evaluation. Radiotherapy for primary thoracic tumors was performed simultaneously on the first day of chemotherapy. Chemotherapy effectiveness was evaluated by radiological examination within one week after the completion of the second cycle of chemotherapy. ;

Study Design

Related Conditions & MeSH terms

Efficacy and Safety

Clinical Trial Details

NCT number	NCT04284215
Study type	Interventional
Source	Guizhou Medical University
Contact
Status	Active, not recruiting
Phase	N/A
Start date	September 1, 2019
Completion date	October 30, 2021

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04759534` - Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia	Phase 3
Not yet recruiting	`NCT05532111` - Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical Trial	N/A
Completed	`NCT06202456` - A Phase IV Study of Huazhi Rougan Granule in the Treatment of Non-alcoholic Simple Fatty Liver	Phase 4
Completed	`NCT04870606` - Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness	Phase 3
Completed	`NCT03660761` - Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors	Phase 2
Active, not recruiting	`NCT03794778` - Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer	Phase 4
Recruiting	`NCT03255343` - Treatment of Non-responding to Conventional Therapy Inoperable Liver Cancers by in Situ Introduction of ImDendrim	N/A
Recruiting	`NCT04197544` - Evaluation of the Implantation of the End-vascular Creation of the Arteriovenous Fistulas in Patients in the University Hospital of Araba. Pilot Study.	N/A
Recruiting	`NCT04518501` - Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer	Phase 1/Phase 2
Completed	`NCT03779776` - The Efficacy and Safety of Early Vitamin AD Supplementation in Very Preterm Infants	N/A
Not yet recruiting	`NCT06218004` - Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell Carcinoma	Phase 2
Enrolling by invitation	`NCT02809079` - Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients	Phase 4
Recruiting	`NCT06194188` - A Phase 2 Clinical Study of CU-20401	Phase 2
Recruiting	`NCT03901235` - MSC Intratissular Injection in Crohn Disease Patients	Phase 1/Phase 2
Completed	`NCT03826004` - Clemastine in Cardiovascular Surgery	N/A
Active, not recruiting	`NCT03623776` - Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC.	Phase 2
Recruiting	`NCT04078399` - Efficacy and Safety of Azacitidine Combined With Interferon in the Treatment of Post-transplant Recurrence	N/A
Not yet recruiting	`NCT06383078` - HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer	Phase 2
Withdrawn	`NCT05481775` - Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Efficacy and Safety of Albumin Paclitaxel Combined With Cisplatin Chemoradiotherapy for Non-resectable Stage III NSCLC

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms